Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Chong, Patrick M ^a   Lynch, Tarah ^a   McCorrister, Stuart ^a   Kibsey, Pamela ^b   Miller, Mark ^c   Gravel, Denise ^a   Westmacott, Garrett R ^a   Mulvey, Michael R ^a,d   Boyd, David ^d   Bridger, Natalie ^e   Bryce, Elizabeth ^f   Conly, John ^g   Dascal, André ^c   De Heer, Janice ^h   Embil, John ⁱ   Embree, Joanne ⁱ   Evans, Gerald ^j   Forgie, Sarah ^k   Frenette, Charles ^l   Haldane, David ^m   German, Gregory ⁿ   Golding, George ^d   Hembroff, Deanna ^o   Henderson, Elizabeth ^p   John, Michael ^q   Johnston, Lynn ^m   Katz, Kevin ^r   Kuhn, Magdalena ^s   Langley, Joanne ^t   Lemieux, Camille ^u   Le Saux, Nicole ^v   Loeb, Mark ^w   Richardson, Susan ^x   McGeer, Allison ^y   Mertz, Dominik ^w   Mitchell, Robyn ^a   Moore, Dorothy ^z   Mounchili, Aboubakar ^a   Pelletier, Suzanne ^aa   Pelude, Linda ^a   Quach, Caroline ^z   Roth, Virginia ^ab   Simor, Andrew ^ac   Smith, Stephanie ^ad   Suh, Kathryn ^ab   Taylor, Geoffrey ^ad   Thomas, Eva ^ae   Turgeon, Nathalie ^af   Vearncombe, Mary ^ac   Vayalumkal, Joseph ^ag   Weiss, Karl ^ah   Wong, Alice ^ai   more..

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b VICTORIA GENERAL HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e Eastern Health Canada   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

^g FOOTHILLS HOSPITAL   (Canada)

^h Interior Health Authority   (Canada)

ⁱ HEALTH SCIENCES CENTRE   (Canada)

^j KINGSTON GENERAL HOSPITAL   (Canada)

^k STOLLERY CHILDREN S HOSPITAL   (Canada)

^l MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^m QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

ⁿ Prince Edward Island   (Canada)

^o University of Northern   (Canada)

^p ALBERTA HEALTH SERVICES   (Canada)

^q LONDON HEALTH SCIENCES CENTRE   (Canada)

^r NORTH YORK GENERAL HOSPITAL   (Canada)

^s London Health Sciences Centre ^*  (Canada)

^t IWK HEALTH CENTRE   (Canada)

^u UNIVERSITY HEALTH NETWORK   (Canada)

^v CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^w HAMILTON HEALTH SCIENCES   (Canada)

^x HOSPITAL FOR SICK CHILDREN   (Canada)

^y MOUNT SINAI HOSPITAL   (Canada)

^z MONTREAL CHILDREN S HOSPITAL   (Canada)

^aa HEALTH SCIENCES NORTH   (Canada)

^ab UNIVERSITY OF OTTAWA   (Canada)

^ac SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^ad UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^ae CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^af LAVAL UNIVERSITY   (Canada)

^ag ALBERTA CHILDREN'S HOSPITAL   (Canada)

^ah MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^ai ROYAL UNIVERSITY HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; FERRIC UPTAKE REGULATOR; METRONIDAZOLE; NITROREDUCTASE; PEPTIDE; PROTEOME; RECA PROTEIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHEMICAL LABELING; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DNA REPAIR; IRON METABOLISM; LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CHROMATOGRAPHY, LIQUID; CLOSTRIDIUM DIFFICILE; CLUSTER ANALYSIS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; METRONIDAZOLE; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84896936012     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082622     Document Type: Article

References (72)

1. Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34: 346-353. (Pubitemid 34062235)
2. Voth DE, Ballard JD (2005) Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18: 247-263. (Pubitemid 40548293)
3. Delaney JAC, Dial S, Barkun A, Suissa S (2007) Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 13: 761-763. (Pubitemid 46698741)
4. O'Connor JR, Johnson S, Gerding DN (2009) Clostridium difficile infection caused by the epidemic B1/NAP1/027 strain. Gastroenterology 136: 1913-1924.
5. Leffler DA, Lamont JT (2009) Treatment of Clostridium difficile-associated disease. Gastroenterology 136: 1899-1912.
6. Bartlett JG (2010) Clostridium difficile: progress and challenges. Ann NY Acad Sci 1213: 62-69.
7. CDC (2005) Severe C. difficile-associated disease in populations previously at low risk - Four states, 2005. MMWR Weekly 54: 1201-1205.
8. Kuijper EJ, Coignard B, Tull P (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12 (Sup 6): 2-18.
9. Rupnik M, Wilcox MH, Gerding DN (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature Reviews Microbiol 7: 526-536.
10. Archibald LK, Banerjee SN, Jarvis WR (2004) Secular trends in hospitalacquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 189: 1585-1589. (Pubitemid 38648285)
11. Deneve C, Janoir C, Poilane I, Fantinato C, Collignon A (2009) New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrobiol Agents 33: S24-S28.
12. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, et al. (2010) The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23: 529-549.
13. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, et al. (2010) Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50: 194-201.
14. Carter GP, Lyras D, Allen DL, Mackin KE, Howarth PM, et al. (2007) Binary toxin production in Clostridium difficile is regulated by CdtR, a LytRTR family response regulator. J Bacteriol 189: 7290-7301. (Pubitemid 47557343)
15. Warmy M, Pepin J, Fang A, Killgore G, Thompson A, et al. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084. (Pubitemid 41338761)
16. Akerlund T, Persson I, Unemo M, Noren T, Svenungsson B, et al. (2008) Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol 46: 1530-1533. (Pubitemid 351563610)
17. Stabler RA, He M, Dawson L, Martin M, Valiente E, et al. (2009) Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biology 10: R102.
18. Peláez T, Alcalá L, Alonso R, Rodriguez-Créixems M, Garcia-Lechuz JM, et al. (2002) Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemo 46: 1647-1650. (Pubitemid 34535177)
19. Freeman J, Stott J, Baines SD, Fawley WN, Wilcox MH (2005) Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 56: 988-989. (Pubitemid 41631938)
20. Löfmark S, Edlund C, Nord CE (2010) Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 50: S16-S23.
21. Nair S, Yadav D, Corpuz M, Pitchumoni CS (1998) Clostridium difficile colitis; factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol 93: 1873-1876. (Pubitemid 29071697)
22. Wong SS, Woo PC, Luk W, Yuen K (1999) Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34: 1-6. (Pubitemid 29216929)
23. Barbut F, Decré D, Burghoffer B, Lesage D, Delisle F, et al. (1999) Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 43: 2607-2611. (Pubitemid 29519537)
24. Johnson S, Sanchez JL, Gerding DN (2000) Metronidazole resistance in Clostridium difficile. Clin Infect Dis 31: 625-626.
25. Brazier JS, Fawley W, Freeman J, Wilcox MH (2001) Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 48: 741-742. (Pubitemid 33100327)
26. Pépin J, Alery M, Valiquette L, Raiche E, Ruel J, et al. (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40: 1591-1597. (Pubitemid 40720808)
27. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, et al. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. CID 40: 1586-1590. (Pubitemid 40720807)
28. Goldstein EJC, Citron DM, Tyrrell KL, Warren YA (2010) Bactericidal activity of telavancin vancomycin, and metronidazole against Clostridium difficile. Anaerobe 16: 220-222.
29. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, et al. (2008) Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemo 62: 1046-1052.
30. Peláez T, Cercenado E, Alcalá L, Marin M, Martin-López A, et al. (2008) Metronidazole resistance in Clostridium difficile is heterogenous. J Clin Microbiol 46: 3028-3032.
31. Huang H, Weintraub A, Fang H, Wu W, Zhang Y, et al. (2010) Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 16: 633-635.
32. Reysset G, Haggoud A, Sebald M (1993) Genetics of resistance of Bacteroides species to 5-nitroimidazole. Clin Infect Dis 16 Suppl 4: S401-S403. (Pubitemid 23157955)
33. Haggoud A, Reysset G, Azeddoug H, Sebauld M (1994) Nucleotide sequence analysis of two 5-nitroimidazole resistance determinants from Bacteroides strains and of a new insertion sequence upstream of the two genes. Antimicrob Agents Chemother 38: 1047-1051. (Pubitemid 24150836)
34. Reysset G (1996) Genetics of 5-nitroimidazole resistance in Bacteroides species. Anaerobe 2: 59-69.
35. Gal M, Brazier JS (2004) Metronidazole resistance in Bacteroides spp. Carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother 54: 109-116. (Pubitemid 39028976)
36. Schapiro JM, Gupta R, Stefansson E, Fang FC, Limaye AP (2004) Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State. J Clin Microbiol 42: 4127-4129. (Pubitemid 39296133)
37. Steffens LS, Nicholson S, Paul LV, Nord CE, Patrick S, et al. (2010) Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole. Res Microbiol 161: 346-354.
38. Diniz CG, Farias LM, Auxiliadora M, Carvalho R, Rocha ER, et al. (2004) Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant. J Antimicrob Chemother 54: 100-108. (Pubitemid 39028975)
39. Jeong J-Y, Mukhopadhyay AK, Dailidiene D, Wang Y, et al. (2000). Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori. J Bacteriol 182: 5082-5090.
40. Kwon DH, Kato M, El-Zaatari FAA, Osato MS, Graham DY (2000) Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance. FEMS Microbiol Lett 188: 197-202. (Pubitemid 30412099)
41. Sisson G, Jeong J-Y, Goodwin A, Bryden L, Rossler N, et al. (2000) Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. Pylori rdxA+ (Nitroreductase) gene. J Bacteriol 182: 5091-5096.
42. Jorgensen MA, Trend MA, Hazell SL, Mendz GL (2001) Potential involvement of several nitroreductases in metronidazole resistance in Helicobacter pylori. Arch Biochem Biophys 392: 180-191. (Pubitemid 32757028)
43. Albert TJ, Dailidiene D, Norton JE, Kalia A, Richmond TA, et al. (2005) Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nature Methods 2: 951-953. (Pubitemid 43108731)
44. Choi SS, Chivers PT, Berg DE (2011) Point mutations in Helicobacter pylori's fur regulatory gene that alter resistance to metronidazole, a prodrug activated by chemical reduction. PLoS One 6:e18236-.
45. Chang K-C, Ho S-W, Yang J-C, Wang J-T (1997) Isolation of a genetic locus associated with metronidazole resistance in Helicobacter pylori. Biochem Biophys Res Com 236: 785-788. (Pubitemid 27384710)
46. Thomson SA, Blaser MJ (1995) Isolation of the Helicobacter pylori recA gene and involvement of the recA region in resistance to low pH. Infect Immun 63: 2185-2193.
47. Tsugawa H, Suzuki H, Muraoka H, Ikeda F, Hirata K, et al. (2011) Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori. Biochem Biophys Res Commun 404: 656-660.
48. Lynch T, Chong P, Zhang J, Hizon R, Du T, et al. (2013) Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS ONE 8:e53757.
49. Moura I, Spigaglia P, Barbanti F, Mastrantonio P (2013) Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes. J Antimicrob Chemother 68: 362-365.
50. Land KM, Johnson PJ (1999) Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa. Drug Resistance Updates 2: 289-294. (Pubitemid 30070453)
51. Hoffman PS, Goodwin A, Johnsen J, Magee K, Van Zanten SJOV (1996) Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: Repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J Bacteriol 178: 4822-4829. (Pubitemid 26321281)
52. Kaihovaara P, Höök-Nikanne J, Uusi-Oukari M, Kosunen TU, Salaspuro M (1998) Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori. J Antimicrob Chemother 41: 171-177. (Pubitemid 28083119)
53. Kaakoush NO, Asencio C, Megraud F, Mendz GL (2009) A redox basis for metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemo 53: 1884-1891.
54. Leitsch D, Burgess AG, Dunn LA, Krauer KG, Tan K, et al. (2011) Pyruvate:ferredoxin oxidoreductase and thioredoxin reductase are involved in 5-nitroimidazole resistance while flavin metabolism is linked to 5-nitroimidazole resistance in Giardia lamblia. J Antimicrob Chemother 66: 1756-1765.
55. Emerson JE, Stabler RA, Wren BW, Fairweather NF (2008) Microarray analysis of the transcriptional responses of Clostridium difficile to environmental and antibiotic stress. J Med Micro 57: 757-764. (Pubitemid 351842069)
56. Carlier JP, Sellier N, Rager MN, Reysset G (1997) Metabolism of a 5- nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis. Antimicrob Agents Chemother 41: 1495-1499. (Pubitemid 27289674)
57. Löfmark S, Fang H, Hedberg M, Edlund C (2005) Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob Agents Chemo 49: 1253-1256. (Pubitemid 40327764)
58. Schaumann R, Petzold S, Fille M, Rodloff AC (2005) Inducible metronidazole resistance in nim-positive and nim-negative Bacteroides fragilis group strains after several passages on metronidazole containing Columbia agar plates. Infection 33: 368-372. (Pubitemid 41552015)
59. Alauzet C, Mory F, Teyssier C, Hallage H, Carlier JP, et al. (2010) Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae. Antimicrob Agents Chemo 54: 60-64.
60. Edwards DI (1993) Nitroimidazole drugs - action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31: 9-20.
61. Tocher JH, Edwards DI (1994) Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases. Biochem Pharmacol 48: 1089-1094. (Pubitemid 24298358)
62. Roca A, Wilcox MM (1997) RecA protein: structure, function, and role in recombinational DNA repair. Prog Nucleic Acid Res Mol Biol 56: 129-223.
63. Maul RW, Sutton MD (2005) Roles of the Escherichia coli RecA protein and the global SOS response in effecting DNA polymerase selection in vivo. J Bacteriol 187: 7607-7618. (Pubitemid 41587699)
64. Ernst FD, Homuth G, Stoof J, Mäder U, Waidner B, et al. (2005) Iron-responsive regulation of the Helicobacter pylori iron-cofactored superoxide dismutase SodB is mediated by Fur. J Bacteriol 187: 3687-3692. (Pubitemid 40705571)
65. Escolar L, Pérez-Martin J, De Lorenzo V (1999) Opening the iron box: Transcriptional metalloregulation by the Fur protein. J Bacteriol 181: 6223-6229. (Pubitemid 29512928)
66. Gancz H, Censini S, Merrell DS (2006) Iron and pH homeostasis intersect at the level of Fur regulation in the gastric pathogen Helicobacter pylori. Infect Immun 74: 602-614. (Pubitemid 43023116)
67. Carpenter BM, Whitmire JM, Merrell DS (2009) This is not your mother's repressor: the complex role of Fur in pathogenesis. Infect Immun 77: 2590-2601.
68. Carpenter BM, Gancz J, Benoit SL, Evans S, Olsen CH, et al. (2010) Mutagenesis of conserved amino acids of Helicobacter pylori Fur reveals residues important for function. J Bacteriol 192: 5037-5052.
69. Butcher J, Sarvan S, Brunzelle MS, Couture J-F, Stintz A (2012) Structure and regulon of Campylobacter jejuni ferric uptake regulator Fur define apo-Fur regulation. Proc Natl Acad Sci USA 109: 10047-10052.
70. Gancz H, Merrell DS (2011) The Helicobacter pylori ferric uptake regulator (Fur) is essential for growth under sodium chloride stress. J Microbiol 49: 294-298.
71. Proctor RA, von Humboldt A (1998) Bacterial energetics and antimicrobial resistance. Drug Resistance Updates 1: 227-235.
72. Roggenkamp A, Hoffmann H, Hornef MW (2004) Growth control of smallcolony variants by genetic regulation of the hemin uptake system. Infect Immun 72: 2254-2262. (Pubitemid 38419941)